Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F23%3AE0110279" target="_blank" >RIV/00843989:_____/23:E0110279 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/22:A2402J4W RIV/00216208:11130/23:10448276 RIV/00064203:_____/23:10448276

Result on the web

<a href="https://link.springer.com/article/10.1007/s00192-022-05359-3" target="_blank" >https://link.springer.com/article/10.1007/s00192-022-05359-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00192-022-05359-3" target="_blank" >10.1007/s00192-022-05359-3</a>

Result language

angličtina

Original language name

Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder

Original language description

Introduction and hypothesis: The aim of this prospective, open-label, multicenter, noncomparative study was to evaluate the efficacy and safety of peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) using the URIS® neuromodulation system as a home treatment for refractory overactive bladder (OAB). Methods: The patients were treated with daily peroneal eTNM® for 30 min over a 6-week period. The primary endpoint was defined as the proportion of responders, i.e., participants with ? 50% reduction in the average daily sum of severe urgency episodes (defined as "I could not postpone voiding but had to rush to the toilet in order not to wet myself") and urgency incontinence episodes. In addition, bladder diary variables, symptom severity (OAB V8 questionnaire), treatment satisfaction (visual analog scale), and pain perception (visual analog scale) were evaluated at baseline (BL), at week 4 (W4), and at the end of treatment (EoT). Safety evaluations included monitoring of the incidence and severity of adverse events (AEs). Changes in time were analyzed using the nonparametric one-way ANOVA Friedman test for categorical variables and the Wilcoxon rank-sum test for the noncategorical variables. Results: In total, 40 subjects were screened and 29 were included in the full analysis set. The proportion of responders was 86% at W4 and 79% at EoT. There was a significant reduction in frequency (p<0.001), number of severe urgency episodes (p< 0.001), number of urgency incontinence episodes (p=0.001), and number of nocturia episodes (p=0.002). There was a significant improvement in the OAB V8 score and treatment satisfaction (both p<0.001). Two mild treatment-related AEs were recorded. Both patients recovered without sequelae and completed the study. Conclusions: Peroneal eTNM® proved to be a highly effective and safe method for the home treatment of OAB, providing a therapeutic response in approximately 80% of patients.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30217 - Urology and nephrology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International urogynecology journal

ISSN

0937-3462

e-ISSN

1433-3023

Volume of the periodical

34

Issue of the periodical within the volume

6

Country of publishing house

GB - UNITED KINGDOM

Number of pages

8

Pages from-to

1253-1260

UT code for WoS article

000855643800001

EID of the result in the Scopus database

2-s2.0-85138438073